Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer

Previous studies suggest beta-adrenergic receptor (β-AR) antagonists (β-blockers) decrease breast cancer progression, tumor metastasis, and patient mortality; however the mechanism for this is unknown. Immunohistochemical analysis of normal and malignant breast tissue revealed overexpression of β1-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Montoya, Alexa, Amaya, Clarissa N., Belmont, Andres, Diab, Nabih, Trevino, Richard, Villanueva, Geri, Rains, Steven, Sanchez, Luis A., Badri, Nabeel, Otoukesh, Salman, Khammanivong, Ali, Liss, Danielle, Baca, Sarah T., Aguilera, Renato J., Dickerson, Erin B., Torabi, Alireza, Dwivedi, Alok K., Abbas, Aamer, Chambers, Karinn, Bryan, Brad A., Nahleh, Zeina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351644/
https://www.ncbi.nlm.nih.gov/pubmed/28031536
http://dx.doi.org/10.18632/oncotarget.14119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351644/
https://www.ncbi.nlm.nih.gov/pubmed/28031536
http://dx.doi.org/10.18632/oncotarget.14119

Ejemplares similares